Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNotebook: Six deals and a name change; Spectrum/CASI, Five Prime/GSK and more

This article was originally published in Scrip

Executive Summary

CASI will develop Spectrum drugs in China; GlaxoSmithKline options Five Prime candidates; MedGenesis licenses technology to Pfizer; Soon-Shiong's NantBioScience initiates cancer collaboration; ImaginAb expands imaging agent pipeline; Akashi acquires DMD drug; and Oxygen changes name to Tenax.

You may also be interested in...



Finance Watch: The Curious Case Of Proteostasis' Short Attack

Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a scathing report. Also, Arena raised more than $350m in an offering after its positive Phase II etrasimod data, and venture capital flows to biopharma firms with big ideas.

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. 

AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq

The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.

Topics

Related Companies

UsernamePublicRestriction

Register

SC026389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel